Literature DB >> 21456601

Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.

Petra Kolenc-Peitl1, Rosalba Mansi, MariaLuisa Tamma, Tanja Gmeiner-Stopar, Marija Sollner-Dolenc, Beatrice Waser, Richard P Baum, Jean Claude Reubi, Helmut R Maecke.   

Abstract

The development of metabolically stable radiolabeled gastrin analogues with suitable pharmacokinetics is a topic of recent research activity. These imaging vectors are of interest because the gastrin/CCK2 receptor is highly overexpressed in different tumors such as medullary thyroid cancer, neuroendocrine tumors, and SCLC. The drawback of current targeting agents is either their metabolic instability or their high kidney uptake. We present the synthesis and in vitro and in vivo evaluation of 11 (111)In-labeled DOTA-conjugated peptides that differ by their spacer between the peptide and the chelate. We introduced uncharged but hydrophilic spacers such as oligoethyleneglycol, serine, and glutamine. The affinity of all radiopeptides was high with IC(50) values between 0.5 and 4.8 nM. The improvement of human serum stability is 500-fold within this series of compounds. In addition the kidney uptake could be lowered distinctly and the tumor-to-kidney ratio improved almost 60-fold if compared with radiotracers having charged spacers such as glutamic acid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21456601     DOI: 10.1021/jm101279a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

Review 1.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.

Authors:  Christof Rottenburger; Guillaume P Nicolas; Lisa McDougall; Felix Kaul; Michal Cachovan; A Hans Vija; Roger Schibli; Susanne Geistlich; Anne Schumann; Tilman Rau; Katharina Glatz; Martin Behe; Emanuel R Christ; Damian Wild
Journal:  J Nucl Med       Date:  2019-09-13       Impact factor: 10.057

3.  Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.

Authors:  Luigi Aloj; Michela Aurilio; Valentina Rinaldi; Laura D'ambrosio; Diego Tesauro; Petra Kolenc Peitl; Theodosia Maina; Rosalba Mansi; Elisabeth von Guggenberg; Lieke Joosten; Jane K Sosabowski; Wouter A P Breeman; Erik De Blois; Stuart Koelewijn; Marleen Melis; Beatrice Waser; Karin Beetschen; Jean Claude Reubi; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

Review 4.  Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.

Authors:  Maximilian Klingler; Anton Amadeus Hörmann; Elisabeth Von Guggenberg
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

5.  Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Authors:  M Fani; H R Maecke; S M Okarvi
Journal:  Theranostics       Date:  2012-05-16       Impact factor: 11.556

Review 6.  Radiolabelled peptides for oncological diagnosis.

Authors:  Peter Laverman; Jane K Sosabowski; Otto C Boerman; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

7.  Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount.

Authors:  Mark W Konijnenberg; Wout A P Breeman; Erik de Blois; Ho Sze Chan; Otto C Boerman; Peter Laverman; Petra Kolenc-Peitl; Marleen Melis; Marion de Jong
Journal:  EJNMMI Res       Date:  2014-08-30       Impact factor: 3.138

8.  Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

Authors:  Anton A Hörmann; Maximilian Klingler; Christine Rangger; Christian Mair; Clemens Decristoforo; Christian Uprimny; Irene J Virgolini; Elisabeth von Guggenberg
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-16

9.  Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.

Authors:  Susanne Kossatz; Rosalba Mansi; Martin Béhé; Peter Czerney; Ingrid Hilger
Journal:  EJNMMI Res       Date:  2013-11-15       Impact factor: 3.138

10.  Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.

Authors:  Theodosia Maina; Mark W Konijnenberg; Petra KolencPeitl; Piotr Garnuszek; Berthold A Nock; Aikaterini Kaloudi; Marko Kroselj; Katja Zaletel; Helmut Maecke; Rosalba Mansi; Paola Erba; Elisabeth von Guggenberg; Alicja Hubalewska-Dydejczyk; Renata Mikolajczak; Clemens Decristoforo
Journal:  Eur J Pharm Sci       Date:  2016-05-14       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.